132 related articles for article (PubMed ID: 24556062)
1. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies.
Rennert G; Rennert HS; Pinchev M; Lavie O
Gynecol Oncol; 2014 May; 133(2):309-13. PubMed ID: 24556062
[TBL] [Abstract][Full Text] [Related]
2. The effect of statins on risk and survival of gynecological malignancies.
Lavie O; Pinchev M; Rennert HS; Segev Y; Rennert G
Gynecol Oncol; 2013 Sep; 130(3):615-9. PubMed ID: 23718932
[TBL] [Abstract][Full Text] [Related]
3. Use of bisphosphonates and risk of postmenopausal breast cancer.
Rennert G; Pinchev M; Rennert HS
J Clin Oncol; 2010 Aug; 28(22):3577-81. PubMed ID: 20567021
[TBL] [Abstract][Full Text] [Related]
4. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
Zhang XS; Zhang YM; Li B; Fan B; Zhao Y; Yang SJ
Gynecol Oncol; 2018 Sep; 150(3):509-514. PubMed ID: 29960711
[TBL] [Abstract][Full Text] [Related]
5. Oral bisphosphonate use and risk of postmenopausal endometrial cancer.
Newcomb PA; Passarelli MN; Phipps AI; Anderson GL; Wactawski-Wende J; Ho GY; O'Sullivan MJ; Chlebowski RT
J Clin Oncol; 2015 Apr; 33(10):1186-90. PubMed ID: 25713431
[TBL] [Abstract][Full Text] [Related]
6. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials.
Liu Y; Qin A; Li T; Qin X; Li S
Gynecol Oncol; 2014 Jun; 133(3):647-55. PubMed ID: 24736024
[TBL] [Abstract][Full Text] [Related]
7. Statin use and the risk of ovarian and endometrial cancers: a meta-analysis.
Wang Y; Ren F; Song Z; Chen P; Liu S; Ouyang L
BMC Cancer; 2019 Jul; 19(1):730. PubMed ID: 31340777
[TBL] [Abstract][Full Text] [Related]
8. Use of bisphosphonates and reduced risk of colorectal cancer.
Rennert G; Pinchev M; Rennert HS; Gruber SB
J Clin Oncol; 2011 Mar; 29(9):1146-50. PubMed ID: 21321296
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
Desai P; Wallace R; Anderson ML; Howard BV; Ray RM; Wu C; Safford M; Martin LW; Rohan T; Manson JE; Simon MS
Gynecol Oncol; 2018 Mar; 148(3):540-546. PubMed ID: 29422345
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk factors and second primary malignancies among women with breast cancer.
Trentham-Dietz A; Newcomb PA; Nichols HB; Hampton JM
Breast Cancer Res Treat; 2007 Oct; 105(2):195-207. PubMed ID: 17186360
[TBL] [Abstract][Full Text] [Related]
11. Are women with breast, endometrial, or ovarian cancer at increased risk for colorectal cancer?
Schoen RE; Weissfeld JL; Kuller LH
Am J Gastroenterol; 1994 Jun; 89(6):835-42. PubMed ID: 8198091
[TBL] [Abstract][Full Text] [Related]
12. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis.
Myung SK; Ju W; Choi HJ; Kim SC;
BJOG; 2009 Dec; 116(13):1697-705. PubMed ID: 19775307
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Alford SH; Rattan R; Buekers TE; Munkarah AR
Cancer; 2015 Feb; 121(3):441-7. PubMed ID: 25533883
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
Schmeler KM; Lynch HT; Chen LM; Munsell MF; Soliman PT; Clark MB; Daniels MS; White KG; Boyd-Rogers SG; Conrad PG; Yang KY; Rubin MM; Sun CC; Slomovitz BM; Gershenson DM; Lu KH
N Engl J Med; 2006 Jan; 354(3):261-9. PubMed ID: 16421367
[TBL] [Abstract][Full Text] [Related]
15. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico.
Salazar-Martinez E; Lazcano-Ponce EC; Gonzalez Lira-Lira G; Escudero-De los Rios P; Salmeron-Castro J; Hernandez-Avila M
Cancer Res; 1999 Aug; 59(15):3658-62. PubMed ID: 10446978
[TBL] [Abstract][Full Text] [Related]
16. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer.
Lambe M; Wigertz A; Garmo H; Walldius G; Jungner I; Hammar N
Cancer Causes Control; 2011 Aug; 22(8):1163-71. PubMed ID: 21688131
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Berchuck A; Schildkraut JM; Wenham RM; Calingaert B; Ali S; Henriott A; Halabi S; Rodriguez GC; Gertig D; Purdie DM; Kelemen L; Spurdle AB; Marks J; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2141-7. PubMed ID: 15598772
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Risks of breast, endometrial, and ovarian cancers after twin births.
Ji J; Försti A; Sundquist J; Hemminki K
Endocr Relat Cancer; 2007 Sep; 14(3):703-11. PubMed ID: 17914100
[TBL] [Abstract][Full Text] [Related]
20. Use of bisphosphonates and risk of breast cancer.
Vestergaard P; Fischer L; Mele M; Mosekilde L; Christiansen P
Calcif Tissue Int; 2011 Apr; 88(4):255-62. PubMed ID: 21253712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
